Forte Biosciences, Inc. Expected to Post FY2024 Earnings of ($0.66) Per Share (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ:FBRXFree Report) – Equities researchers at Brookline Capital Management issued their FY2024 earnings per share estimates for shares of Forte Biosciences in a note issued to investors on Wednesday, May 29th. Brookline Capital Management analyst K. Raja expects that the company will post earnings of ($0.66) per share for the year. Brookline Capital Management has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Forte Biosciences’ current full-year earnings is ($0.59) per share. Brookline Capital Management also issued estimates for Forte Biosciences’ FY2025 earnings at ($0.68) EPS.

Forte Biosciences (NASDAQ:FBRXGet Free Report) last announced its earnings results on Monday, March 18th. The company reported ($0.04) earnings per share for the quarter.

Separately, LADENBURG THALM/SH SH upgraded Forte Biosciences from a “neutral” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Monday, April 8th.

Read Our Latest Analysis on Forte Biosciences

Forte Biosciences Stock Performance

Forte Biosciences stock opened at $0.59 on Monday. The business’s 50-day simple moving average is $0.69 and its two-hundred day simple moving average is $0.67. The company has a market cap of $21.64 million, a PE ratio of -0.67 and a beta of 0.46. Forte Biosciences has a fifty-two week low of $0.38 and a fifty-two week high of $1.06.

Institutional Trading of Forte Biosciences

A hedge fund recently bought a new stake in Forte Biosciences stock. Fred Alger Management LLC acquired a new stake in Forte Biosciences, Inc. (NASDAQ:FBRXFree Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,838,965 shares of the company’s stock, valued at approximately $1,217,000. Fred Alger Management LLC owned 5.07% of Forte Biosciences as of its most recent SEC filing. Institutional investors own 77.63% of the company’s stock.

About Forte Biosciences

(Get Free Report)

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.

See Also

Earnings History and Estimates for Forte Biosciences (NASDAQ:FBRX)

Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with's FREE daily email newsletter.